公开(公告)号：US20180346952A1

公开(公告)日：2018-12-06

申请号：US15955046

申请日：2018-04-17

Applicant: Amunix Operating Inc.

Inventor： Volker Schellenberger ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P.C Stemmer ,  Nathan C. Geething

IPC: C12P21/02 ,  C12N15/62 ,  C07K16/32 ,  C07K14/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/81 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C07K16/40 ,  A61K38/00

CPC classification number: C12P21/02 ,  A61K38/00 ,  C07K14/00 ,  C07K14/70521 ,  C07K14/7155 ,  C07K14/8125 ,  C07K16/18 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31 ,  C07K2319/70 ,  C07K2319/74 ,  C12N15/625

Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.

公开(公告)号：US20180319862A1

公开(公告)日：2018-11-08

申请号：US15773540

申请日：2016-11-04

Applicant: Juno Therapeutics, Inc.

Inventor： Lucas James THOMPSON ,  Valerie ODEGARD ,  Blythe SATHER ,  Archana BRAHMANDAM

IPC: C07K14/705 ,  C07K14/73 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  A61P35/00

CPC classification number: C07K14/70521 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/033 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/715 ,  C07K2319/74 ,  C07K2319/75 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/998

Abstract: Provided are chimeric receptors for engineering cells for adoptive therapy, including T cells, and the genetically engineered cells. In some aspects, also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects. In some embodiments, the cells, such as T cells, contain genetically engineered antigen receptors that specifically bind to antigens, such as a chimeric antigen receptor (CAR), and which contain an intracellular signaling domain capable of inducing TRAF6-mediated signaling. In some embodiments, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence.

公开(公告)号：US20180298074A1

公开(公告)日：2018-10-18

申请号：US16020469

申请日：2018-06-27

Applicant: VIB VZW ,  UNIVERSITEIT GENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ MONTPELLIER 2 ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER

Inventor： Jan TAVERNIER ,  Jennyfer BULTINCK ,  Frank PEELMAN ,  Gilles UZE

IPC: C07K14/525 ,  C07K16/32 ,  C07K16/28 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K14/525 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2869 ,  C07K16/32 ,  C07K2317/569 ,  C07K2319/00 ,  C07K2319/74

Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

公开(公告)号：US20180251503A1

公开(公告)日：2018-09-06

申请号：US15715499

申请日：2017-09-26

Applicant: Memorial Sloan-Kettering Cancer Center

Inventor： Mahiuddin Ahmed ,  Nai-Kong V. Cheung

IPC: C07K14/47 ,  C07K16/30 ,  C07K16/46 ,  A61K38/17 ,  C07K16/18 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K14/47 ,  A61K38/1709 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3053 ,  C07K16/3084 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/74

Abstract: The present invention provides, among other things, dimeric multispecific binding agents (e.g., fusion proteins comprising antibody components) that have improved properties over multispecific binding agents without the capability of dimerization.

公开(公告)号：US10010602B2

公开(公告)日：2018-07-03

申请号：US15167911

申请日：2016-05-27

Applicant: Reber Genetics Co., Ltd.

Inventor： Yu-Hsin Chien ,  Meng-Ju Tsai ,  Pao-Yen Lai ,  Wei-I Chou ,  Hsiu-Kang Chang

IPC: A61K39/12 ,  C07K14/005 ,  C07K14/21 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/21 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/55 ,  C07K2319/74 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2770/10022 ,  C12N2770/10034

Abstract: A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.

公开(公告)号：US20180179291A1

公开(公告)日：2018-06-28

申请号：US15739199

申请日：2016-06-24

Applicant: JCR Pharmaceuticals Co., Ltd.

Inventor： Hiroyuki Sonoda ,  Kenichi Takahashi

IPC: C07K16/28 ,  C07K14/475

CPC classification number: C07K16/2881 ,  A61K38/22 ,  A61K39/395 ,  A61K2039/505 ,  A61P25/00 ,  C07K14/475 ,  C07K14/48 ,  C07K16/28 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/74 ,  C12N5/10 ,  C12N15/09

Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.

公开(公告)号：US20180170989A1

公开(公告)日：2018-06-21

申请号：US15883925

申请日：2018-01-30

Applicant: VIB VZW ,  UNIVERSITEIT GENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ MONTPELLIER 2 ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER

Inventor： Jan Tavernier ,  Jennyfer Bultinck ,  Frank Peelman ,  Gilles Uze

IPC: C07K14/525 ,  C07K16/32 ,  C07K16/28 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K14/525 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2869 ,  C07K16/32 ,  C07K2317/569 ,  C07K2319/00 ,  C07K2319/74

Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

公开(公告)号：US09994638B2

公开(公告)日：2018-06-12

申请号：US15159831

申请日：2016-05-20

Applicant: Immunwork Inc.

Inventor： Tse-Wen Chang ,  Hsing-Mao Chu ,  Chien-Jen Lin ,  Chun-Yu Lin

IPC: A61K47/48 ,  C07K16/10 ,  C07K17/02 ,  C07K16/18 ,  C07K16/12 ,  A61K31/137 ,  C07K16/28 ,  C07K14/565 ,  C07K7/08 ,  C07K14/00 ,  C07K17/06 ,  A61K47/65 ,  A61K47/60 ,  A61K47/64 ,  A61K47/68

CPC classification number: C07K16/283 ,  A61K31/137 ,  A61K47/60 ,  A61K47/64 ,  A61K47/65 ,  A61K47/6849 ,  A61K47/6883 ,  C07K7/08 ,  C07K14/001 ,  C07K14/565 ,  C07K16/1027 ,  C07K16/1203 ,  C07K16/18 ,  C07K16/2839 ,  C07K16/2881 ,  C07K17/02 ,  C07K17/06 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/70 ,  C07K2319/74

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

公开(公告)号：US20180148503A1

公开(公告)日：2018-05-31

申请号：US15817673

申请日：2017-11-20

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： David A. Scheinberg ,  Tao Dao ,  Cheng Liu ,  Hong Liu ,  Yiyang Xu ,  Su Yan

IPC: C07K16/28 ,  A61K47/68 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K39/0011 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/00 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  G01N33/57492 ,  G01N2333/705

Abstract: The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL). The antibodies or antigen binding proteins may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

公开(公告)号：US09976166B2

公开(公告)日：2018-05-22

申请号：US14977035

申请日：2015-12-21

Applicant: Amunix Operating Inc.

Inventor： Volker Schellenberger ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P. C. Stemmer ,  Nathan C. Geething

IPC: C07K16/18 ,  C07K16/24 ,  C12P21/02 ,  C07K16/40 ,  C07K14/00 ,  C07K14/81 ,  C07K14/705 ,  C07K14/715 ,  C07K16/28 ,  C07K16/32 ,  C12N15/62 ,  A61K38/00

CPC classification number: C12P21/02 ,  A61K38/00 ,  C07K14/00 ,  C07K14/70521 ,  C07K14/7155 ,  C07K14/8125 ,  C07K16/18 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31 ,  C07K2319/70 ,  C07K2319/74 ,  C12N15/625

Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.